{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:22:16Z","timestamp":1788175336190,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BMS foundation"},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11899-024-00746-7","type":"journal-article","created":{"date-parts":[[2025,1,12]],"date-time":"2025-01-12T21:27:39Z","timestamp":1736717259000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL)"],"prefix":"10.1007","volume":"20","author":[{"given":"Katherine B.","family":"Case","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela B.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"issue":"11","key":"746_CR1","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","volume":"8","author":"ZR Cai","year":"2022","unstructured":"Cai ZR, Chen ML, Weinstock MA, Kim YH, Novoa RA, Linos E. Incidence trends of primary cutaneous T-Cell lymphoma in the US From 2000 to 2018: a SEER population data analysis. JAMA Oncol. 2022;8(11):1690\u20132. https:\/\/doi.org\/10.1001\/jamaoncol.2022.3236.","journal-title":"JAMA Oncol"},{"issue":"Suppl 4","key":"746_CR2","doi-asserted-by":"publisher","first-page":"iv30","DOI":"10.1093\/annonc\/mdy133","volume":"29","author":"R Willemze","year":"2018","unstructured":"Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M, Committee EG. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv30\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdy133.","journal-title":"Ann Oncol"},{"issue":"20","key":"746_CR3","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375\u201390. https:\/\/doi.org\/10.1182\/blood-2016-01-643569.","journal-title":"Blood"},{"issue":"13","key":"746_CR4","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","volume":"49","author":"EC Benton","year":"2013","unstructured":"Benton EC, Crichton S, Talpur R, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859\u201368. https:\/\/doi.org\/10.1016\/j.ejca.2013.04.018.","journal-title":"Eur J Cancer"},{"issue":"13","key":"746_CR5","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","volume":"49","author":"NHS Mehta-Shah","year":"2013","unstructured":"Mehta-Shah NHS, Ansell S, et al. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome. Eur J Cancer. 2013;49(13):2859\u201368.","journal-title":"Eur J Cancer"},{"issue":"12","key":"746_CR6","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.3109\/10428194.2016.1173210","volume":"57","author":"HH Danish","year":"2016","unstructured":"Danish HH, Liu S, Jhaveri J, Flowers CR, Lechowicz MJ, Esiashvili N, Khan MK. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and S\u00e9zary syndrome. Leuk Lymphoma. 2016;57(12):2813\u20139. https:\/\/doi.org\/10.3109\/10428194.2016.1173210.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"746_CR7","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1002\/ajh.23756","volume":"89","author":"RA Wilcox","year":"2014","unstructured":"Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89(8):837\u201351. https:\/\/doi.org\/10.1002\/ajh.23756.","journal-title":"Am J Hematol"},{"issue":"5","key":"746_CR8","doi-asserted-by":"publisher","first-page":"522","DOI":"10.6004\/jnccn.2020.0022","volume":"18","author":"N Mehta-Shah","year":"2020","unstructured":"Mehta-Shah N, Horwitz SM, Ansell S, et al. NCCN guidelines insights: primary cutaneous lymphomas, version 2.2020. J Natl Compr Canc Netw. 2020;18(5):522\u201336. https:\/\/doi.org\/10.6004\/jnccn.2020.0022.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"746_CR9","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood-2014-07-588236","volume":"125","author":"CF Hughes","year":"2015","unstructured":"Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71\u201381. https:\/\/doi.org\/10.1182\/blood-2014-07-588236.","journal-title":"Blood"},{"issue":"1","key":"746_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","volume":"7","author":"M Duvic","year":"2006","unstructured":"Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006;7(1):51\u20138. https:\/\/doi.org\/10.3816\/CLM.2006.n.039.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"4","key":"746_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1093\/annonc\/mdp508","volume":"21","author":"PL Zinzani","year":"2010","unstructured":"Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol. 2010;21(4):860\u20133. https:\/\/doi.org\/10.1093\/annonc\/mdp508.","journal-title":"Ann Oncol"},{"issue":"33","key":"746_CR12","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","volume":"30","author":"RQP Dummer","year":"2012","unstructured":"Dummer RQP, Becker JC, Hasan B, Karrasch M, Whittaker S, Morris S, Weichenthal M, Stadler R, Bagot M, Cozzio A, Bernengo MG, Knobler R. Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012. J Clin Oncol. 2012;30(33):4091\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.39.8065.","journal-title":"J Clin Oncol"},{"issue":"18","key":"746_CR13","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","volume":"119","author":"SM Horwitz","year":"2012","unstructured":"Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood. 2012;119(18):4115\u201322. https:\/\/doi.org\/10.1182\/blood-2011-11-390211.","journal-title":"Blood"},{"issue":"3","key":"746_CR14","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/annonc\/mdy207","volume":"30","author":"P Quaglino","year":"2019","unstructured":"Quaglino P, Maule M, Prince HM, et al. Global patterns of care in advanced stage mycosis fungoides\/Sezary syndrome: a multicenter retrospective follow-up study from the cutaneous lymphoma international consortium. Ann Oncol. 2019;30(3):494. https:\/\/doi.org\/10.1093\/annonc\/mdy207.","journal-title":"Ann Oncol"},{"issue":"1","key":"746_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41409-023-02122-0","volume":"59","author":"A Goyal","year":"2024","unstructured":"Goyal A, O\u2019Leary D, Foss F. Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis. Bone Marrow Transplant. 2024;59(1):41\u201351. https:\/\/doi.org\/10.1038\/s41409-023-02122-0.","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"746_CR16","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1182\/blood-2016-01-694117","volume":"128","author":"JPM-DK Nicolay","year":"2016","unstructured":"Nicolay JPM-DK, Schroeder A, Brechmann M, M\u00f6bs M, G\u00e9raud C, Assaf C, Goerdt S, Krammer PH, G\u00fclow K. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-\u03baB. Blood. 2016;128(6):805\u201315.","journal-title":"Blood"},{"issue":"9","key":"746_CR17","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1182\/blood.2022018669","volume":"142","author":"JPMS Nicolay","year":"2023","unstructured":"Nicolay JPMS, Albrecht JD, Assaf C, Dippel E, Stadler R, Wehkamp U, Wobser M, Zhao J, Burghaus I, Schneider S, G\u00fclow K, Goerdt S, Sch\u00fcrch CM, Utikal JS, Krammer PH. Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study. Blood. 2023;142(9):794\u2013805.","journal-title":"Blood"},{"issue":"10094","key":"746_CR18","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","volume":"390","author":"HM Prince","year":"2017","unstructured":"Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician\u2019s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390(10094):555\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(17)31266-7.","journal-title":"Lancet"},{"issue":"9","key":"746_CR19","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","volume":"19","author":"YH Kim","year":"2018","unstructured":"Kim YH, Bagot M, Pinter-Brown L, et al. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(9):1192\u2013204. https:\/\/doi.org\/10.1016\/S1470-2045(18)30379-6.","journal-title":"Lancet Oncol"},{"issue":"15","key":"746_CR20","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/CMAR.S330908","volume":"6","author":"AOT Pelcovits","year":"2023","unstructured":"Pelcovits AOT, Olszewski AJ. Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma. Cancer Manag Res. 2023;6(15):989\u201398. https:\/\/doi.org\/10.2147\/CMAR.S330908.","journal-title":"Cancer Manag Res"},{"issue":"11","key":"746_CR21","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1517\/14712590903348135","volume":"9","author":"G Manoukian","year":"2009","unstructured":"Manoukian G, Hagemeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther. 2009;9(11):1445\u201351.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"746_CR22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","volume":"19","author":"EDM Olsen","year":"2001","unstructured":"Olsen EDM, Frankel A, Kim Y, Martin A, Vonderheid E, Jegasothy B, Wood G, Gordon M, Heald P, Oseroff A, Pinter-Brown L, Bowen G, Kuzel T, Fivenson D, Foss F, Glode M, Molina A, Knobler E, Stewart S, Cooper K, Stevens S, Craig F, Reuben J, Bacha P, Nichols J. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol. 2001;19(2):376\u201388.","journal-title":"J Clin Oncol"},{"issue":"11","key":"746_CR23","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","volume":"28","author":"HMDM Prince","year":"2010","unstructured":"Prince HMDM, Martin A, Sterry W, Assaf C, Sun Y, Straus D, Acosta M, Negro-Vilar A. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2010;28(11):1870\u20137. https:\/\/doi.org\/10.1200\/JCO.2009.26.2386.","journal-title":"J Clin Oncol"},{"issue":"6","key":"746_CR24","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1111\/cas.14906","volume":"112","author":"HAK Kawai","year":"2021","unstructured":"Kawai HAK, Maruyama D, Yamamoto K, Kiyohara E, Terui Y, Fukuhara N, Miyagaki T, Tokura Y, Sakata-Yanagimoto M, Igarashi T, Kuroda J, Fujita J, Uchida T, Ishikawa T, Yonekura K, Kato K, Nakanishi T, Nakai K, Matsunaga R, Tobinai K. Phase II study of E7777 in Japanese patients with relapsed\/refractory peripheral and cutaneous T-cell lymphoma. Cancer Sci. 2021;112(6):2426\u201335.","journal-title":"Cancer Sci"},{"issue":"Supplement 1","key":"746_CR25","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1182\/blood-2022-166916","volume":"140","author":"F Foss","year":"2022","unstructured":"Foss F, Kim YH, Prince M, Kuzel TM, Yannakou CK, Ooi CE, Xing D, Sauter N, Singh P, Czuczman M, Duvic M. Efficacy and safety of E7777 (improved purity denileukin diftitox [ONTAK]) in patients with relapsed or refractory cutaneous T-Cell lymphoma: results from pivotal study 302. Blood. 2022;140(Supplement 1):1491\u20132.","journal-title":"Blood"},{"key":"746_CR26","unstructured":"Citius pharmaceuticals receives FDA approval for LYMPHIR\u2122 (denileukin diftitox-cxdl) immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. Updated August 8, 2024. Accessed August 12, 2024, https:\/\/www.prnewswire.com\/news-releases\/citius-pharmaceuticals-receives-fda-approval-for-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma-302217630.html"},{"issue":"5","key":"746_CR27","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ekir.2022.02.014","volume":"7","author":"H Izzedine","year":"2022","unstructured":"Izzedine H, Mathian A, Amoura Z, Ng JH, Jhaveri KD. Anticancer drug-induced capillary leak syndrome. Kidney Int Rep. 2022;7(5):945\u201353. https:\/\/doi.org\/10.1016\/j.ekir.2022.02.014.","journal-title":"Kidney Int Rep"},{"key":"746_CR28","unstructured":"Ontak (denileukin diftitox) [ package insert]. US Food and Drug Administration.; 2020. Accessed August 12, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/103767s5144lbl.pdf"},{"issue":"23","key":"746_CR29","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.1182\/bloodadvances.2021004710","volume":"5","author":"SMSJ Horwitz","year":"2021","unstructured":"Horwitz SMSJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician\u2019s choice in cutaneous T-cell lymphoma: final data. BLood Adv. 2021;5(23):5098\u2013106.","journal-title":"BLood Adv"},{"issue":"10","key":"746_CR30","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.1182\/bloodadvances.2023011030","volume":"8","author":"PL Zinzani","year":"2024","unstructured":"Zinzani PL, Salles G, Moskowitz AJ, et al. Nivolumab plus brentuximab vedotin for relapsed\/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma. Blood Adv. 2024;8(10):2400\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2023011030.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"746_CR31","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1182\/blood-2023-178279","volume":"142","author":"C Poh","year":"2023","unstructured":"Poh C, Lynch RC, Warren EH, et al. Brentuximab vedotin in combination with nivolumab in CD30+ malignancies refractory to brentuximab vedotin. Blood. 2023;142(Supplement 1):3060\u20133060. https:\/\/doi.org\/10.1182\/blood-2023-178279.","journal-title":"Blood"},{"key":"746_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.ejca.2021.01.054","volume":"148","author":"YH Kim","year":"2021","unstructured":"Kim YH, Prince HM, Whittaker S, et al. Response to brentuximab vedotin versus physician\u2019s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: an ALCANZA sub-analysis. Eur J Cancer. 2021;148:411\u201321. https:\/\/doi.org\/10.1016\/j.ejca.2021.01.054.","journal-title":"Eur J Cancer"},{"issue":"7","key":"746_CR33","doi-asserted-by":"publisher","first-page":"e1011524","DOI":"10.1080\/2162402X.2015.1011524","volume":"4","author":"X Ni","year":"2015","unstructured":"Ni X, Langridge T, Duvic M. Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab. Oncoimmunology. 2015;4(7):e1011524. https:\/\/doi.org\/10.1080\/2162402X.2015.1011524.","journal-title":"Oncoimmunology"},{"issue":"18","key":"746_CR34","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","volume":"29","author":"EA Olsen","year":"2011","unstructured":"Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the international society for cutaneous lymphomas, the United States cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the european organisation for research and treatment of cancer. J Clin Oncol. 2011;29(18):2598\u2013607. https:\/\/doi.org\/10.1200\/JCO.2010.32.0630.","journal-title":"J Clin Oncol"},{"issue":"6","key":"746_CR35","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","volume":"157","author":"KENT Hirotsu","year":"2021","unstructured":"Hirotsu KENT, Khodadoust MS, Wang JY, Rieger KE, Strelo J, Hong E, Kim YH, Kwong BY. Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or s\u00e9zary syndrome. JAMA Dermatol. 2021;157(6):700\u20137.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"746_CR36","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","volume":"44","author":"JYHK Wang","year":"2020","unstructured":"Wang JYHK, Neal TM, Raghavan SS, Kwong BY, Khodadoust MS, Brown RA, Novoa RA, Kim YH, Rieger KE. Histopathologic characterization of mogamulizumab-associated rash. Am J Surg Pathol. 2020;44(12):1666\u20137.","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"746_CR37","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","volume":"155","author":"LCK Chen","year":"2019","unstructured":"Chen LCK, Staser KW, Mehta-Shah N, Schaffer A, Rosman IS, Musiek A. Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response. JAMA Dermatol. 2019;155(8):968\u201371.","journal-title":"JAMA Dermatol"},{"key":"746_CR38","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1111\/jdv.20228","volume":"38","author":"G Avallone","year":"2024","unstructured":"Avallone G, Roccuzzo G, Pileri A, et al. Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: a systematic review. J Eur Acad Dermatol Venereol. 2024;38:1675\u20136. https:\/\/doi.org\/10.1111\/jdv.20228.","journal-title":"J Eur Acad Dermatol Venereol."},{"issue":"2","key":"746_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/jdv.18549","volume":"37","author":"M Beylot-Barry","year":"2023","unstructured":"Beylot-Barry M, Booken N, Weishaupt C, et al. Impact of blood involvement on efficacy and time to response with mogamulizumab in mycosis fungoides and Sezary syndrome. J Eur Acad Dermatol Venereol. 2023;37(2):311\u20136. https:\/\/doi.org\/10.1111\/jdv.18549.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"746_CR40","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.clml.2020.09.003","volume":"21","author":"P Porcu","year":"2021","unstructured":"Porcu P, Hudgens S, Horwitz S, et al. Quality of life effect of the anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in patients with cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2021;21(2):97\u2013105. https:\/\/doi.org\/10.1016\/j.clml.2020.09.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"3","key":"746_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/1078-0432.CCR-21-2781","volume":"28","author":"DS Hong","year":"2022","unstructured":"Hong DS, Rixe O, Chiu VK, et al. Mogamulizumab in combination with nivolumab in a phase I\/II study of patients with locally advanced or metastatic solid tumors. Clin Cancer Res. 2022;28(3):479\u201388. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2781.","journal-title":"Clin Cancer Res"},{"key":"746_CR42","doi-asserted-by":"publisher","unstructured":"Ninosu N, Melchers S, Kappenstein M, et al. Mogamulizumab combined with extracorporeal photopheresis as a novel therapy in erythrodermic cutaneous T-cell lymphoma. Cancers (Basel). 2023;16(1). https:\/\/doi.org\/10.3390\/cancers16010141.","DOI":"10.3390\/cancers16010141"},{"issue":"26","key":"746_CR43","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood-2017-06-792382","volume":"130","author":"M Battistella","year":"2017","unstructured":"Battistella M, Leboeuf C, Ram-Wolff C, et al. KIR3DL2 expression in cutaneous T-cell lymphomas: expanding the spectrum for KIR3DL2 targeting. Blood. 2017;130(26):2900\u20132. https:\/\/doi.org\/10.1182\/blood-2017-06-792382.","journal-title":"Blood"},{"issue":"8","key":"746_CR44","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1470-2045(19)30320-1","volume":"20","author":"M Bagot","year":"2019","unstructured":"Bagot M, Porcu P, Marie-Cardine A, et al. IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. Lancet Oncol. 2019;20(8):1160\u201370. https:\/\/doi.org\/10.1016\/S1470-2045(19)30320-1.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"746_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood-2023-173806","volume":"142","author":"M Bagot","year":"2023","unstructured":"Bagot M, Kim YH, Geskin LJ, et al. Lacutamab in patients with relapsed and refractory s\u00e8zary syndrome: results from the tellomak phase 2 trial. Blood. 2023;142(Supplement 1):185\u2013185. https:\/\/doi.org\/10.1182\/blood-2023-173806.","journal-title":"Blood"},{"key":"746_CR46","unstructured":"ASH. FDA places partial hold on T-cell lymphomas treatment studies. Accessed August 7, 2024, 2024. https:\/\/ashpublications.org\/ashclinicalnews\/news\/7682\/FDA-Places-Partial-Hold-on-T-Cell-Lymphomas"},{"key":"746_CR47","unstructured":"FDA lifts partial clinical hold on lacutamab IND. Targeted oncology. Accessed August 12, 2024, https:\/\/www.targetedonc.com\/view\/fda-lifts-partial-clinical-hold-on-lacutamab-ind"},{"issue":"7","key":"746_CR48","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1182\/bloodadvances.2021005714","volume":"6","author":"CH Wu","year":"2022","unstructured":"Wu CH, Wang L, Yang CY, et al. Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models. Blood Adv. 2022;6(7):2290\u2013302. https:\/\/doi.org\/10.1182\/bloodadvances.2021005714.","journal-title":"Blood Adv"},{"issue":"21","key":"746_CR49","doi-asserted-by":"publisher","first-page":"6411","DOI":"10.1158\/1078-0432.CCR-17-0613","volume":"23","author":"P Aftimos","year":"2017","unstructured":"Aftimos P, Rolfo C, Rottey S, et al. Phase I dose-escalation study of the anti-CD70 antibody ARGX-110 in advanced malignancies. Clin Cancer Res. 2017;23(21):6411\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-0613.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"746_CR50","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/cncr.34005","volume":"128","author":"N Leupin","year":"2022","unstructured":"Leupin N, Zinzani PL, Morschhauser F, et al. Cusatuzumab for treatment of CD70-positive relapsed or refractory cutaneous T-cell lymphoma. Cancer. 2022;128(5):1004\u201314. https:\/\/doi.org\/10.1002\/cncr.34005.","journal-title":"Cancer"},{"issue":"12","key":"746_CR51","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","volume":"146","author":"S Samimi","year":"2010","unstructured":"Samimi S, Benoit B, Evans K, et al. Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression. Arch Dermatol. 2010;146(12):1382\u20138. https:\/\/doi.org\/10.1001\/archdermatol.2010.200.","journal-title":"Arch Dermatol"},{"issue":"12","key":"746_CR52","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archdermatol.2012.2089","volume":"148","author":"FJP \u00c7etin\u00f6zman","year":"2012","unstructured":"\u00c7etin\u00f6zman FJP, Vermeer MH, Willemze R. Differential expression of programmed death-1 (PD-1) in s\u00e9zary syndrome and mycosis fungoides. Arch Dermatol. 2012;148(12):1379\u201385.","journal-title":"Arch Dermatol"},{"issue":"1","key":"746_CR53","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/DAD.0b013e31821c35cb","volume":"34","author":"K Kantekure","year":"2012","unstructured":"Kantekure K, Yang Y, Raghunath P, et al. Expression patterns of the immunosuppressive proteins PD-1\/CD279 and PD-L1\/CD274 at different stages of cutaneous T-cell lymphoma\/mycosis fungoides. Am J Dermatopathol. 2012;34(1):126\u20138. https:\/\/doi.org\/10.1097\/DAD.0b013e31821c35cb.","journal-title":"Am J Dermatopathol"},{"issue":"14","key":"746_CR54","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood.2020009655","volume":"138","author":"JDJ Park","year":"2021","unstructured":"Park JDJ, Wartewig T, Ringbloom KG, Martinez-Escala ME, Choi S, Thomas JJ, Doukas PG, Yang J, Snowden C, Law C, Lee Y, Lee K, Zhang Y, Conran C, Tegtmeyer K, Mo SH, Pease DR, Jothishankar B, Kwok PY, Abdulla FR, Pro B, Louissaint A, Boggon TJ, Sosman J, Guitart J, Rao D, Ruland J, Choi J. Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood. 2021;138(14):1225\u201336.","journal-title":"Blood"},{"issue":"3","key":"746_CR55","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1182\/bloodadvances.2020002371","volume":"5","author":"S Beygi","year":"2021","unstructured":"Beygi S, Fernandez-Pol S, Duran G, et al. Pembrolizumab in mycosis fungoides with PD-L1 structural variants. Blood Adv. 2021;5(3):771\u20134. https:\/\/doi.org\/10.1182\/bloodadvances.2020002371.","journal-title":"Blood Adv"},{"issue":"1","key":"746_CR56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO.19.01056","volume":"38","author":"MS Khodadoust","year":"2020","unstructured":"Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizumab in relapsed and refractory mycosis fungoides and sezary syndrome: a multicenter phase II study. J Clin Oncol. 2020;38(1):20\u20138. https:\/\/doi.org\/10.1200\/JCO.19.01056.","journal-title":"J Clin Oncol"},{"issue":"16","key":"746_CR57","doi-asserted-by":"publisher","first-page":"4435","DOI":"10.1182\/bloodadvances.2022009575","volume":"7","author":"E Bachy","year":"2023","unstructured":"Bachy E, Savage KJ, Huang H, et al. Treating relapsed\/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study. Blood Adv. 2023;7(16):4435\u201347. https:\/\/doi.org\/10.1182\/bloodadvances.2022009575.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"746_CR58","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood-2020-143354","volume":"136","author":"CTN Querfeld","year":"2020","unstructured":"Querfeld CTN, Palmer J, Martinez XU, Abdulla F, Wu X, Rosen ST, Zain J. Phase 1 results of anti-PD-ligand 1 (Durvalumab) & lenalidomide in patients with cutaneous T cell lymphoma and correlation with programmed death ligand 1 expression and gene expression profile. Blood. 2020;136(Supplement 1):20. https:\/\/doi.org\/10.1182\/blood-2020-143354.","journal-title":"Blood"},{"issue":"Supplement 1","key":"746_CR59","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1182\/blood-2023-188053","volume":"142","author":"C Querfeld","year":"2023","unstructured":"Querfeld C, Chen L, Wu X, et al. Preliminary analysis demonstrates durvalumab (Anti-PD-L1) & Lenalidomide is superior to single-agent durvalumab (anti-PD-L1) in refractory\/advanced cutaneous T cell lymphoma in a randomized phase 2 trial. Blood. 2023;142(Supplement 1):3077\u20133077. https:\/\/doi.org\/10.1182\/blood-2023-188053.","journal-title":"Blood"},{"key":"746_CR60","doi-asserted-by":"publisher","first-page":"989","DOI":"10.2147\/CMAR.S330908","volume":"15","author":"A Pelcovits","year":"2023","unstructured":"Pelcovits A, Ollila TA, Olszewski AJ. Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma. Cancer Manag Res. 2023;15:989\u201398. https:\/\/doi.org\/10.2147\/CMAR.S330908.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"746_CR61","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41375-019-0622-6","volume":"34","author":"H Kamijo","year":"2020","unstructured":"Kamijo H, Miyagaki T, Takahashi-Shishido N, et al. Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47. Leukemia. 2020;34(3):845\u201356. https:\/\/doi.org\/10.1038\/s41375-019-0622-6.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"746_CR62","doi-asserted-by":"publisher","first-page":"6376","DOI":"10.1182\/blood-2022-167670","volume":"140","author":"ZWX Han","year":"2022","unstructured":"Han ZWX, Yuan Y, Qin H, Su C, Zain J, Akilov OE, Rosen ST, Feng M, Querfeld C. Blockade of the immune checkpoint CD47 by TTI-621 potentiates the response to anti-PD-L1 in cutaneous T cell lymphoma. Blood. 2022;140(Supplement 1):6376\u20137. https:\/\/doi.org\/10.1182\/blood-2022-167670.","journal-title":"Blood"},{"issue":"11","key":"746_CR63","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(21)00271-4","volume":"8","author":"C Querfeld","year":"2021","unstructured":"Querfeld C, Thompson JA, Taylor MH, et al. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sezary syndrome: a multicentre, phase 1 study. Lancet Haematol. 2021;8(11):e808\u201317. https:\/\/doi.org\/10.1016\/S2352-3026(21)00271-4.","journal-title":"Lancet Haematol"},{"issue":"8","key":"746_CR64","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"27","author":"SM Ansell","year":"2021","unstructured":"Ansell SM, Maris MB, Lesokhin AM, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(8):2190\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3706.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"746_CR65","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41375-018-0305-8","volume":"33","author":"C Cristofoletti","year":"2019","unstructured":"Cristofoletti C, Bresin A, Picozza M, et al. Blood and skin-derived sezary cells: differences in proliferation-index, activation of PI3K\/AKT\/mTORC1 pathway and its prognostic relevance. Leukemia. 2019;33(5):1231\u201342. https:\/\/doi.org\/10.1038\/s41375-018-0305-8.","journal-title":"Leukemia"},{"issue":"11","key":"746_CR66","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41408-018-0138-8","volume":"8","author":"JJ Han","year":"2018","unstructured":"Han JJ, O\u2019Byrne M, Stenson MJ, et al. Prognostic and therapeutic significance of phosphorylated STAT3 and protein tyrosine phosphatase-6 in peripheral-T cell lymphoma. Blood Cancer J. 2018;8(11):110. https:\/\/doi.org\/10.1038\/s41408-018-0138-8.","journal-title":"Blood Cancer J"},{"issue":"23","key":"746_CR67","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1182\/blood.2021012536","volume":"138","author":"KEM Lee","year":"2021","unstructured":"Lee KEM, Yang L, Ng S, Snowden C, Khodadoust M, Brown RA, Trum NA, Querfeld C, Doan LT, Song J, Zhang H, Gru AA, Wood GS, Wada DA, Shanmugam V, Haun PL, Aster JC, Duncan LM, Guitart J, Weinstock DM, Nardi V, Choi J. Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway. Blood. 2021;138(23):2435\u201340.","journal-title":"Blood"},{"issue":"3","key":"746_CR68","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3324\/haematol.2020.274506","volume":"107","author":"AN Bastidas Torres","year":"2022","unstructured":"Bastidas Torres AN, Cats D, Out-Luiting JJ, et al. Deregulation of JAK2 signaling underlies primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma. Haematologica. 2022;107(3):702\u201314. https:\/\/doi.org\/10.3324\/haematol.2020.274506.","journal-title":"Haematologica"},{"issue":"8","key":"746_CR69","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1182\/blood-2017-08-802470","volume":"131","author":"SMKR Horwitz","year":"2018","unstructured":"Horwitz SMKR, Porcu P, Oki Y, Moskowitz A, Perez M, Myskowski P, Officer A, Jaffe JD, Morrow SN, Allen K, Douglas M, Stern H, Sweeney J, Kelly P, Kelly V, Aster JC, Weaver D, Foss FM, Weinstock DM. Activity of the PI3K-\u03b4, \u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2018;131(8):888\u201398.","journal-title":"Blood"},{"issue":"2","key":"746_CR70","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clml.2019.10.013","volume":"20","author":"CDR Carlo-Stella","year":"2020","unstructured":"Carlo-Stella CDR, Scarfo L, Barde PJ, Nair A, Locatelli SL, Morello L, Magagnoli M, Vakkalanka S, Viswanadha S, Ferreri AJM. A first-in-human study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor, in patients with relapsed\/refractory hematologic malignancies: results from the european study. Clin Lymphoma Myeloma Leuk. 2020;20(2):78\u201386.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"746_CR71","doi-asserted-by":"publisher","unstructured":"Huen A, Haverkos BM, Zain J, et al. Phase I\/Ib study of tenalisib (RP6530), a dual PI3K delta\/gamma inhibitor in patients with relapsed\/refractory T-cell lymphoma. Cancers (Basel). 2020;12(8). https:\/\/doi.org\/10.3390\/cancers12082293.","DOI":"10.3390\/cancers12082293"},{"issue":"1","key":"746_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3324\/haematol.2022.281875","volume":"109","author":"SP Iyer","year":"2024","unstructured":"Iyer SP, Huen A, Ai WZ, et al. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed\/refractory T-cell lymphoma: results from a phase I\/II open-label multicenter study. Haematologica. 2024;109(1):209\u201319. https:\/\/doi.org\/10.3324\/haematol.2022.281875.","journal-title":"Haematologica"},{"issue":"26","key":"746_CR73","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood.2021013379","volume":"138","author":"AJGP Moskowitz","year":"2021","unstructured":"Moskowitz AJGP, Jacobsen E, Ruan J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa A, Dowd J, Obadi O, Pomerantz L, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus D, Kumar P, Dogan A, Hollmann T, Drill E, Rademaker J, Schoder H, Inghirami G, Weinstock DM, Horwitz SM. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas. Blood. 2021;138(26):2828\u201337.","journal-title":"Blood"},{"issue":"Supplement 1","key":"746_CR74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2023-172512","volume":"142","author":"E Jacobsen","year":"2023","unstructured":"Jacobsen E, Maruyama D, Porcu P, Tobinai K, Allen PB, Ishitsuka K, Tsukasaki K, Kusumoto S, Foss F, Yamauchi N, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tsutsumi S, Horwitz SM. Valemetostat for relapsed or refractory peripheral T-cell lymphomas: primary results from a phase 1 trial. Blood. 2023;142(Supplement 1):303. https:\/\/doi.org\/10.1182\/blood-2023-172512.","journal-title":"Blood"},{"issue":"4","key":"746_CR75","first-page":"1681","volume":"53","author":"CSM Ishikawa","year":"2018","unstructured":"Ishikawa CSM, Mori N. Anti-adult T-cell leukemia\/lymphoma activity of cerdulatinib, a dual SYK\/JAK kinase inhibitor. Int J Oncol. 2018;53(4):1681\u201390.","journal-title":"Int J Oncol"},{"issue":"2","key":"746_CR76","doi-asserted-by":"publisher","first-page":"103390","DOI":"10.1016\/j.retram.2023.103390","volume":"71","author":"PA Atilla","year":"2023","unstructured":"Atilla PA, Atilla E. Are we there yet? Cellular therapies for cutaneous T cell lymphoma. Curr Res Transl Med. 2023;71(2):103390. https:\/\/doi.org\/10.1016\/j.retram.2023.103390.","journal-title":"Curr Res Transl Med"},{"issue":"4","key":"746_CR77","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"746_CR78","doi-asserted-by":"publisher","first-page":"968395","DOI":"10.3389\/fimmu.2022.968395","volume":"13","author":"V To","year":"2022","unstructured":"To V, Evtimov VJ, Jenkin G, Pupovac A, Trounson AO, Boyd RL. CAR-T cell development for cutaneous T cell Lymphoma: current limitations and potential treatment strategies. Front Immunol. 2022;13:968395. https:\/\/doi.org\/10.3389\/fimmu.2022.968395.","journal-title":"Front Immunol"},{"key":"746_CR79","doi-asserted-by":"publisher","unstructured":"Rouce RH HL, Smith TS, Yang L, Boriskie B, Srinivasan M, Zhang H, Perconti S, Mehta B, Dakhova O, Grilley BJ, Heslop HE, Brenner MK, Mamonkin M. Early signals of anti-tumor efficacy and safety with autologous CD5.CAR T-cells in patients with refractory\/relapsed T-Cell LYMPHOMA. Blood. 2021;138(Supplement 1):654. https:\/\/doi.org\/10.1182\/blood-2021-154142","DOI":"10.1182\/blood-2021-154142"},{"key":"746_CR80","doi-asserted-by":"publisher","unstructured":"Hill LC, Rouce RH, Wu MJ, et al. Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed\/refractory mature T-cell lymphomas. Blood. 2024;143(13), 1231\u20131241. https:\/\/doi.org\/10.1182\/blood.2023022204","DOI":"10.1182\/blood.2023022204"},{"issue":"9","key":"746_CR81","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1172\/JCI94306","volume":"127","author":"CA Ramos","year":"2017","unstructured":"Ramos CA, Ballard B, Zhang H, et al. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. J Clin Invest. 2017;127(9):3462\u201371. https:\/\/doi.org\/10.1172\/JCI94306.","journal-title":"J Clin Invest"},{"issue":"Supplement 1","key":"746_CR82","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1182\/blood-2021-148102","volume":"138","author":"NS Grover","year":"2021","unstructured":"Grover NS, Ivanova A, Moore DT, et al. CD30-directed CAR-T cells co-expressing CCR4 in relapsed\/refractory hodgkin lymphoma and CD30+ cutaneous T cell lymphoma. Blood. 2021;138(Supplement 1):742\u2013742. https:\/\/doi.org\/10.1182\/blood-2021-148102.","journal-title":"Blood"},{"issue":"Supplement 1","key":"746_CR83","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1182\/blood-2021-146990","volume":"138","author":"ML Marques-Piubelli","year":"2021","unstructured":"Marques-Piubelli ML, Solis Soto L, Iyer SP, et al. CD70 expression in mature T-cell lymphomas. Blood. 2021;138(Supplement 1):4493\u20134493. https:\/\/doi.org\/10.1182\/blood-2021-146990.","journal-title":"Blood"},{"key":"746_CR84","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/01.HS9.0000843940.96598.e2","volume":"6","author":"SPSR Iyer","year":"2022","unstructured":"Iyer SPSR, Ho PJ, Hu B, Zain J, Prica A, Weng W, Kim YH, Khodadoust MS, Palomba ML, Foss FM, Tipton K, Cullingford EL, He Q, Sharma A. Horwitz SM the cobalt-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic crispr-cas9-engineered CAR T cells in patients with relapsed\/refractory (r\/r) T-cell malignancies. HemaSphere. 2022;6:163\u20134. https:\/\/doi.org\/10.1097\/01.HS9.0000843940.96598.e2.","journal-title":"HemaSphere"},{"issue":"7","key":"746_CR85","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/2211-5463.13625","volume":"13","author":"ZMJ Wang","year":"2023","unstructured":"Wang ZMJ, Zhang H, Ramakrishna R, Mintzlaff D, Mathes DW, Pomfret EA, Lucia MS, Gao D, Haverkos BM, Wang Z. CCR4-IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T-cell lymphoma in a mouse CTCL model. FEBS Open Bio. 2023;13(7):1309\u201319.","journal-title":"FEBS Open Bio"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-024-00746-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-024-00746-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-024-00746-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:19:42Z","timestamp":1769044782000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-024-00746-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["746"],"URL":"https:\/\/doi.org\/10.1007\/s11899-024-00746-7","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"17 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}],"article-number":"5"}}